Evidence map›Paper›PMID 21996456›Full record

ArticleClinical immunology (Orlando, Fla.)2011

Islet allograft tolerance in the absence of invariant natural killer T cells.

Xiufeng Chu, Elizabeth Kilpatrick, Xiang Xiao, Wentao Liu, Gulcin Demirci, Mark Exley, Xian C Li

Abstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xiufeng ChuDepartment of Microbiology, Peking University Health Sciences, Beijing, China.
Elizabeth Kilpatrick
Xiang Xiao
Wentao Liu
Gulcin Demirci
Mark Exley
Xian C Li
Beth Israel Deaconess Medical Center · USPeking University · CN

Funding

Modulation of innate immune cells to create transplant toleranceR01AI080779 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Xian Chang Li · 2011 to 2026
$5.2M
Modulation of innate immune cells to create transplant toleranceR56AI080779 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LI, XIAN CHANG · 2010 to 2010
$435k
NIAID NIH HHS R01 AI080779NIAID NIH HHS R56 AI080779
6 · The paper itself

Abstract

The invariant NKT cells are involved in both immunity and immune tolerance. However, their roles in transplant models remain controversial. We studied the role of NKT cells in the allograft response using two different strains of NKT deficient mice (CD1d-/- and Jα18-/- mice), and found that CD1d-/- and Jα18-/- mice rejected islet allografts with a similar kinetics as wild type B6 mice. Treatment of CD1d-/- and Jα18-/- mice with donor specific transfusion and anti-CD154 induced donor specific tolerance, which was identical to similarly treated wt B6 mice. The islet allograft tolerance requires Foxp3(+) Tregs. In the periphery, Foxp3(+) Tregs in CD1d-/-, Jα18-/-, and wt B6 mice were comparable both phenotypically and functionally. In addition, CD1d-/- and Jα18-/- CD4(+) T cells (non-Tregs) could be readily converted to Foxp3(+) Tregs by TGF-β in vitro. Our data suggest that islet allograft tolerance can be successfully established without invariant NKT cells.

Indexed as

AnimalsAntigens, CD1dCD40 LigandForkhead Transcription FactorsGraft RejectionIslets of Langerhans TransplantationMiceMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBANatural Killer T-CellsT-Lymphocytes, RegulatoryTransforming Growth Factor betaTransplantation ToleranceAntigens, CD1dCD40 LigandForkhead Transcription FactorsFoxp3 protein, mouseTransforming Growth Factor beta

Identifiers

PMID21996456
PMCPMC3221878
OpenAlexW2023535531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.